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Special article

A Randomized Study of How Physicians
Interpret Research Funding Disclosures
Aaron S. Kesselheim, M.D., J.D., M.P.H., Christopher T. Robertson, Ph.D., J.D.,
Jessica A. Myers, Ph.D., Susannah L. Rose, Ph.D., Victoria Gillet, B.A.,
Kathryn M. Ross, M.B.E., Robert J. Glynn, Ph.D., Steven Joffe, M.D.,
and Jerry Avorn, M.D.

A bs t r ac t
Background

The effects of clinical-trial funding on the interpretation of trial results are poorly
understood. We examined how such support affects physicians’ reactions to trials
with a high, medium, or low level of methodologic rigor.
Methods

We presented 503 board-certified internists with abstracts that we designed describing clinical trials of three hypothetical drugs. The trials had high, medium, or
low methodologic rigor, and each report included one of three support disclosures:
funding from a pharmaceutical company, NIH funding, or none. For both factors
studied (rigor and funding), one of the three possible variations was randomly selected for inclusion in the abstracts. Follow-up questions assessed the physicians’
impressions of the trials’ rigor, their confidence in the results, and their willingness to prescribe the drugs.
Results

The 269 respondents (53.5% response rate) perceived the level of study rigor accurately. Physicians reported that they would be less willing to prescribe drugs tested
in low-rigor trials than those tested in medium-rigor trials (odds ratio, 0.64; 95%
confidence interval [CI], 0.46 to 0.89; P = 0.008) and would be more willing to prescribe drugs tested in high-rigor trials than those tested in medium-rigor trials
(odds ratio, 3.07; 95% CI, 2.18 to 4.32; P<0.001). Disclosure of industry funding, as
compared with no disclosure of funding, led physicians to downgrade the rigor of
a trial (odds ratio, 0.63; 95% CI, 0.46 to 0.87; P = 0.006), their confidence in the results (odds ratio, 0.71; 95% CI, 0.51 to 0.98; P = 0.04), and their willingness to prescribe the hypothetical drugs (odds ratio, 0.68; 95% CI, 0.49 to 0.94; P = 0.02).
Physicians were half as willing to prescribe drugs studied in industry-funded trials
as they were to prescribe drugs studied in NIH-funded trials (odds ratio, 0.52; 95%
CI, 0.37 to 0.71; P<0.001). These effects were consistent across all levels of methodologic rigor.
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Conclusions

Physicians discriminate among trials of varying degrees of rigor, but industry sponsorship negatively influences their perception of methodologic quality and reduces
their willingness to believe and act on trial findings, independently of the trial’s quality. These effects may influence the translation of clinical research into practice.
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large proportion of clinical trials of new treatments is funded by the
pharmaceutical industry.1,2 There is increasing concern over how such support can affect the design of these trials3 and the reporting
of the results.4-9 Some practitioners may be swayed
by potential bias in industry-supported publications to use certain medications more widely than
would be appropriate, whereas other practitioners
may be skeptical about the validity of companyfunded research.10 In the past two decades, to ensure full transparency in the reporting of clinical
trials, disclosure of financial support has become
the norm in medical research publications.11-13
Some biomedical journals include disclosures in
the abstracts themselves, where their effect on
readers might be greatest.14
Financial disclosure may not fully address the
problem of potential bias in published research
results.15,16 One study showed that physicians ignored disclosure statements,17 whereas other studies have shown that disclosure of substantial conflicts of interest can lead clinicians to discount
the reported results of a trial.18-20 Some reports
suggest that the disclosure of conflicts of interest can have a paradoxical effect,21 such as enhancing the trustworthiness of the discloser.22
The methodologic rigor of a trial, not its funding disclosure, should be a primary determinant
of its credibility. Skepticism about results that is
based on a trial’s funding sources may be less
appropriate for well-controlled, double-blind,
randomized trials than for poorly controlled or
unblinded trials, in which conflicts of interest
may have a stronger effect on interpretation of
the data. However, little is known about how
information concerning study design interacts
with information concerning funding sources to
influence physicians’ interpretation of research.
We therefore conducted a randomized study involving simulated research abstracts to assess
the role that disclosure plays in physicians’ interpretation of the results of medical research.

Me thods
Development of the Survey Instrument
and Study Oversight

We developed hypothetical scenarios in which
three new drugs were being evaluated for the
treatment of disorders commonly encountered in
primary care: hyperlipidemia, diabetes, and an1120
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gina. “Lampytinib” would be used for dyslipidemia in patients who had unacceptable side effects from statins, “bondaglutaraz” would be
used for diabetes and low levels of high-density
lipoprotein cholesterol in patients who were taking metformin and a sulfonylurea and who were
unwilling or unable to add insulin, and “provasinab” would be used for angina in patients with
untreatable multivessel coronary disease who
were taking maximal doses of beta-blockers.
Since internists report that they frequently read
only the abstracts when reviewing the medical
literature,23 we created abstracts describing trials
of these drugs in which we varied the drug being
tested, the trial’s methodologic rigor, and the
funding source. For each drug, one trial had a
high level of rigor, one had a medium level of
rigor, and one had a low level of rigor. The features defining these levels were based on guidelines24,25 and on our experience in conducting
randomized trials26,27 and in studying evidencebased drug-evaluation and prescribing practices28,29 (Table 1). Differences in methodologic
rigor among the trials were consistent across
drugs. All the trials had similar effect sizes, and
statistically significant results.
We then added a variable describing the trial’s
funding status. Each abstract included one of
three variations: no funding source mentioned,
funding by the National Institutes of Health
(NIH), or funding by a pharmaceutical company,
with financial involvement in that company on
the part of the lead author. (Companies named
in the disclosure statements were randomly selected from the top 12 global pharmaceutical
enterprises.30)
Assigning one of the three conditions to each
of the three variables (drug, study design, and
funding source), we created 27 different abstracts
describing a hypothetical new-drug trial. The abstracts, along with the study protocol, are provided in the Supplementary Appendix, available
with the full text of this article at NEJM.org. The
survey was pretested among 12 physicians certified in internal medicine.
The study was approved by the institutional
review board at Brigham and Women’s Hospital,
with written informed consent implied by the
participant’s completion of the survey. There were
no agreements concerning confidentiality of the
data between the authors and the institutions
providing financial support for the study.
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Survey Sample

The American Board of Internal Medicine (ABIM)
maintains a list of diplomates with active certification and maintenance of certification. The
data set included demographic characteristics
and information about medical training and responses to the ABIM Practice Characteristics
Survey.31,32 From a potential sample of 45,398
physicians, we randomly identified 514 who reported spending 40% or more of their time and
21 hours or more per month in activities related
to patient care and spending 50% or less of their
time in the intensive care unit, the emergency
department, or the cardiac catheterization laboratory. Of these possible participants, 11 had
noncurrent contact information, resulting in a
potential sample of 503 physicians.

Table 1. Characteristics Used to Differentiate Trials of Hypothetical New
Drugs, According to Methodologic Rigor.
Characteristic

Level of Rigor
High

Medium

Randomization

Randomized

Randomized

Randomized

Blinding

Double-blind

Single-blind

Open-label

Active

Active

Usual care

Comparator
Dropout rate (%)
Sample size (no. of
patients)
End point
Patient population
Length of follow-up (mo)
Report of safety

Low

<9

13

19

5322

964

483

Mortality

Surrogate

Surrogate

Representative Representative

Not
representative

36

12

4

Drug appears
to be safe

Drug appears
to be safe

No report

Survey Administration

Between July 2011 and October 2011, physicians
in the sample received two postcards and three
e-mail messages from ABIM indicating that they
had been randomly selected to participate in a
study investigating how physicians make prescribing decisions. These communications included
the names of the sponsoring institutions and the
lead investigators, a link to the online survey, an
opportunity to opt out, and an offer of a $50
honorarium on completion of the survey (see the
Supplementary Appendix). Physicians who did not
respond were mailed a printed version of the invitation along with a $5 bill and an offer of $45 on
completion of the survey. Those who still did not
respond received a telephone reminder.
Participants were presented with three abstracts, each of which described a trial of a different hypothetical new drug. Participants were
told to assume that the hypothetical drug had
recently been approved by the Food and Drug Administration and was covered by insurance and
that the abstract was from a “high-impact” biomedical journal and written by academic physicians at established U.S. universities. We randomly varied the level of methodologic rigor and
the disclosure so that the three abstracts that
the physicians received described trials at each
level of methodologic rigor and with each disclosure variation.

7-point Likert scale. Physicians were asked about
their likelihood of prescribing the new drug (ranging from a score of 1 for “very unlikely to prescribe” to a score of 7 for “very likely to prescribe”),
the level of methodologic rigor of the trial (ranging from a score of 1 for “not at all rigorous”
[low rigor] to a score of 7 for “very rigorous”
[high rigor]), and their confidence in the study
investigators’ conclusions (ranging from a score
of 1 for “not confident at all” to a score of 7 for
“very confident”). Secondary outcomes were participants’ rating of the importance of the trial20
and their level of interest in reading the full article. (These questionnaires are provided in the
Supplementary Appendix.)
After reading the third abstract, participants
were asked to estimate how many abstracts describing trials of medications they had read in
biomedical journals in the past month and to respond to the following question: “Do you think
that pharmaceutical company funding is likely to
influence the outcome of scientific studies about
the efficacy and safety of pharmaceuticals in favor of the drug in question?” Finally, participants
were asked about any financial support they had
received from drug, device, or other medically
related companies in the previous year.33
Statistical Analysis

For each question, we estimated a hierarchical
Each abstract was followed by the same set of proportional-odds regression model, using the apquestions, with the choice of answers based on a propriate Likert-scale response as the outcome.
Dependent Measures and Variables
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This model included a random intercept for each
physician to account for within-physician correlation of responses across abstracts, as well as
fixed effects for methodologic rigor (low, medium,
or high), disclosure statement (industry funding,
NIH funding, or no statement), and drug. A second model included interactions between the indicators for funding source and methodologic
rigor.34 Because we developed the three hypothetical drugs solely to obtain data about the effects of the level of methodologic rigor and variation of disclosure, we did not separately analyze
differences among the drugs.
To investigate the association between characteristics of the physicians and survey responses,
we created proportional-odds models that included random intercepts for physicians; indicators for the variables describing methodologic
rigor, type of disclosure statement, and drug; and
terms for physician characteristics (i.e., age, sex,
location of medical school [U.S. vs. non-U.S.], type
of practice [general internal medicine vs. subspecialty], proportion of time spent in clinical
care [≥80% vs. <80%], hours per month spent in
clinical care [≥80 vs. <80], acceptance of gifts from
industry [any vs. none], and opinion about whether industry funding influences the outcome of
trials in favor of the drug being tested [a score
of 6 or higher vs. a score of 5 or lower on the
7-point scale, with higher numbers indicating a
perception of a stronger influence]).

R e sult s
Characteristics of the Respondents

Of the 503 physicians who were invited to participate in the survey, 269 responded (a 53.5% response rate); 192 (71.4%) responded online (spending a median of 14 minutes), and 77 (28.6%)
responded by returning a paper copy of the survey. We evaluated the responses of the 263 physicians who answered all the questions for one or
more abstracts.
The demographic and practice characteristics
of the respondents did not differ significantly
from those of the nonrespondents (Table 2).
Most of the respondents (75.5% [188 of 249])
reported accepting at least one type of industry
support. Respondents generally agreed with the
statement that industry funding could influence
the outcome of clinical trials of pharmaceutical
agents in favor of the drug in question (mean
1122
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score, 5.4 [out of a possible 7.0]; 95% confidence
interval [CI], 4.0 to 6.9). Responses to other questions are provided in the Supplementary Appendix.
Effect of Methodologic Rigor

We found strong associations between the methodologic rigor of the hypothetical trials and physicians’ perceptions of rigor. In comparisons
with trials having a medium level of rigor, physicians were less likely to identify low-rigor trials
as rigorous (odds ratio, 0.55; 95% CI, 0.40 to
0.76; P<0.001) (Fig. 1A) and were more likely to
report high-rigor trials as rigorous (odds ratio,
3.95; 95% CI, 2.81 to 5.55; P<0.001). Similarly, in
comparisons with medium-rigor trials, physicians had less confidence in the results of lowrigor trials (odds ratio, 0.48; 95% CI, 0.35 to 0.66;
P<0.001) and more confidence in the results of
high-rigor trials (odds ratio, 2.73; 95% CI, 1.95 to
3.82; P<0.001) (Fig. 1B) and would be less likely
to prescribe drugs described in low-rigor trials
(odds ratio, 0.64; 95% CI, 0.46 to 0.89; P=0.008)
and more willing to prescribe drugs described in
high-rigor trials (odds ratio, 3.07; 95% CI, 2.18 to
4.32; P<0.001) (Fig. 1C).
Effect of Disclosure variations

We found clear associations between the funding
disclosure variations and physicians’ perceptions
of a trial’s rigor and results. Regardless of the
actual study design, physicians were less likely to
view a trial as having a high level of rigor if funding by a pharmaceutical company was disclosed
than if no disclosure statement was included
(odds ratio, 0.63; 95% CI, 0.46 to 0.87; P = 0.006)
(Fig. 2A). Similarly, in comparisons with trials
for which no funding was listed and regardless
of the study design, physicians were less likely to
have confidence in the results of trials funded by
industry (odds ratio, 0.71; 95% CI, 0.51 to 0.98;
P = 0.04) (Fig. 2B) and were less willing to prescribe drugs described in such trials (odds ratio,
0.68; 95% CI, 0.49 to 0.94; P = 0.02) (Fig. 2C).
These effects were even greater when industryfunded trials were compared with trials described as having NIH support.
In comparisons with NIH-funded trials, respondents were also less likely to describe industryfunded trials as “important” (odds ratio, 0.59; 95%
CI, 0.42 to 0.82; P = 0.002), and were less likely
to want to read the full article (odds ratio, 0.67;
95% CI, 0.47 to 0.95; P = 0.03). In comparisons
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Table 2. Personal and Professional Characteristics of Physicians in the Survey Sample.*
Respondents†
(N = 241)

Nonrespondents
(N = 262)

48

48

45–53

45–53

162 (67.2)

183 (69.8)

0.53

United States

136 (56.4)

140 (53.4)

0.50

Other than United States

105 (43.6)

122 (46.6)

>80 hr/mo

78 (32.4)

86 (32.8)

≤80 hr/mo

162 (67.2)

176 (67.2)

Characteristic
Age — yr

P Value
0.82

Median
Interquartile range
Male sex — no. of physicians (%)
Medical-school location — no. of physicians (%)

Time spent in clinical care activities — no. of physicians (%)‡

Clinical time devoted to primary care — %

0.94
0.35

Median
Interquartile range

80

70

20–91

6–95

No. of journal abstracts read in past month relating to
prescription drugs§

NA

Median

4

Interquartile range

2–8

Industry support received — no. of physicians/total no. (%)¶

188/249 (75.5)

NA

* NA denotes not available.
†	Demographic data could not be matched to 22 of 263 respondents (8.4%). These data therefore remain in the group of
nonrespondents.
‡	Data were missing for 2 physicians.
§ Results are based on data for 248 physicians.
¶ Industry support included drug samples, meals, educational support, honoraria, and support for travel to meetings.
Data were available for 249 physicians.

between industry-funded trials and trials with no
funding statement, the differences were smaller
with respect to respondents’ ratings of the importance of the trial (odds ratio, 0.88; 95% CI,
0.63 to 1.22; P = 0.43) and their desire to read the
full article (odds ratio, 0.88; 95% CI, 0.63 to 1.23;
P = 0.46).

trials and P = 0.56 for low-rigor trials vs. mediumrigor trials). We found no interaction between
methodologic rigor and disclosure with respect
to variations in physicians’ perceptions of the
rigor of a trial or their confidence in the results
(data not shown).
Effect of Physicians’ Characteristics

Interaction between Methodologic Rigor
and Disclosure variations

The reduction in physicians’ willingness to prescribe drugs studied in industry-funded trials as
compared with drugs studied in trials without
funding disclosures was consistent across levels
of methodologic rigor (P = 0.87 for high-rigor trials vs. medium-rigor trials and P = 0.83 for lowrigor trials vs. medium-rigor trials). The greater
willingness to prescribe drugs described in NIHfunded trials was also constant across rigor levels (P = 0.81 for high-rigor trials vs. medium-rigor

n engl j med 367;12

Irrespective of the disclosure and level of methodologic rigor, physicians who strongly agreed
that funding by pharmaceutical companies can
influence the results of a trial (score of 6 or 7 on
the Likert scale) were less likely to prescribe the
hypothetical drugs than were physicians with
lower scores (odds ratio, 0.58; 95% CI, 0.37 to
0.91; P = 0.02). For all the abstracts presented,
U.S.-trained physicians were substantially less
likely to say they would be willing to prescribe
the hypothetical drugs than were physicians who
were trained elsewhere (odds ratio, 0.44; 95% CI,
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3.95 (95% CI, 2.81–5.55)
P<0.001

Odds Ratio

3.0
2.0
1.5
1.0

0.5

0.55 (95% CI, 0.40–0.76)
P<0.001
Low

Medium

High

drugs (odds ratio, 1.65; 95% CI, 1.04 to 2.61;
P = 0.03). Adjustment for physicians’ characteristics did not alter the effect estimates of methodologic rigor or disclosure statement, indicating
that the randomization effectively balanced these
characteristics.

Level of Rigor

B Confidence in Results
5.0
4.0

Odds Ratio

3.0

2.73 (95% CI, 1.95–3.82)

Discussion

P<0.001

2.0
1.5
1.0

0.5

0.48 (95% CI, 0.35–0.66)
P<0.001
Low

Medium

High

Level of Rigor

C Willingness to Prescribe Drug
5.0
4.0
3.07 (95% CI, 2.18–4.32)

Odds Ratio

3.0

P<0.001

2.0
1.5
1.0

0.64 (95% CI, 0.46–0.89)

P=0.008

0.5

Low

Medium

High

Level of Rigor

0.27 to 0.70; P = 0.001). Physicians who were older than the median age of 48 years for the sample
were more likely than the younger physicians to
report that they would prescribe the simulated
1124
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Figure 1. Association between Methodologic Rigor
and Physicians’ Perceptions of Hypothetical New-Drug
Trials.
Panel A shows the physicians’ perception of a trial’s
level of rigor, Panel B their confidence in the results,
and Panel C their willingness to prescribe the drug being
studied. For each survey question, using Likert-scale responses, we determined the likelihood that the physician
would assign a higher score to trials randomly assigned
to have low or high rigor, as compared with trials with
medium rigor, with adjustment for the disclosure variable. Open circles designate the point estimates for
the odds ratios, with the 95% confidence intervals (CI)
indicated by the vertical lines.

A Perception of Trial’s Rigor
5.0
4.0

of

n engl j med 367;12

In this randomized study, we found that practicing internists understood and appreciated methodologic differences when they read abstracts
describing hypothetical studies of new drugs.
They discounted small, poorly designed trials
and assigned greater validity to large trials that
tested clinical end points. We also found that respondents downgraded the credibility of industry-funded trials, as compared with the same trials randomly characterized as having NIH
funding or having no source of support listed.
The magnitude of this reduction in perceived
methodologic rigor was about the same as that
for low-rigor trials as compared with mediumrigor trials. Physicians’ skepticism of industryfunded research affected their responses to highrigor and low-rigor trials similarly.
Well-publicized controversies related to industry-funded research may help explain these findings. Reports have emerged of trials that withheld critical data35-37 or that presented positive
results while withholding negative results.38,39
Other concerns stem from reports of industryfinanced articles that were ghostwritten40 or
published primarily as instruments of marketing.41 Physicians’ skepticism of industry-funded
research may be a response to such trends.
These findings have important implications.
Despite the occasional scientific and ethical lapses
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A Perception of Trial’s Rigor
1.25

0.63 (95% CI, 0.46–0.87) 0.50 (95% CI, 0.36–0.69)
P=0.006
P<0.001

1.00

Odds Ratio

Figure 2. Association between Disclosure Variable
and Physicians’ Perceptions of Hypothetical New-Drug
Trials.
Panel A shows the physicians’ perception of a trial’s
level of rigor, Panel B their confidence in the results,
and Panel C their willingness to prescribe the drug being
studied. For each survey question, using Likert-scale
responses, we determined the likelihood that the physician would assign a higher score to trials randomly assigned to funding by a pharmaceutical company, as
compared with trials having no funding source listed
and trials described as being funded by the National
Institutes of Health (NIH), adjusting for the methodologic rigor variable. Open circles designate the point estimates for the odds ratios, with the 95% confidence intervals indicated by the vertical lines.

0.75

0.50

Industry vs. None

Industry vs. NIH

Funding

n engl j med 367;12

B Confidence in Results
1.25

0.71 (95% CI, 0.51–0.98) 0.51 (95% CI, 0.36–0.70)
P<0.001
P=0.04

Odds Ratio

1.00

0.75

0.50

Industry vs. None

Industry vs. NIH

Funding

C Physician Willingness to Prescribe Drug
1.25

0.68 (95% CI, 0.49–0.94) 0.52 (95% CI, 0.37–0.71)
P=0.02
P<0.001

1.00

Odds Ratio

in trials funded by pharmaceutical companies, it
is also true that the pharmaceutical industry has
supported many major drug trials that have been
of particular clinical importance.42 Excessive skepticism concerning trials supported by industry
could hinder the appropriate translation of the
results into practice. For example, after publishing the results of a large, well-designed trial describing a new use for a widely prescribed class
of drugs,43 a leading biomedical journal noted that
many of its readers believed that the results of
the trial did not justify a change in clinical management, citing industry funding as a key reason
for this conclusion.44
The results of our study were based on physicians’ responses to descriptions of hypothetical
trials of three new drugs, each of which was
described in a single trial with varying attributes,45 whereas actual prescribing behavior integrates drug information from many sources.
Nevertheless, prescribing decisions made when a
drug is first approved may rely principally on a
single published study, as presented in these
scenarios. Our response rate was similar to the
mean rate in published surveys of physicians,46
and our respondents were similar to other internists in terms of the characteristics we measured.47 However, unmeasured variables may
have differed between respondents and nonrespondents, contributing to bias in our sample.
Finally, the findings from this survey of boardcertified internists may not be generalizable to
other specialties.48
Pharmaceutical companies seeking to enhance the appropriate use of important new
products or to expand the appropriate uses of

0.75

0.50

Industry vs. None

Industry vs. NIH

Funding

existing products must address the attitudes that
our survey revealed,49,50 so that the credibility of
the results of industry-supported trials is more
likely to be based on methodologic rigor than on
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funding sources. Exactly how to change such
attitudes was not the subject of this research.
Currently, journal reviewers and editors, those
who conduct systematic reviews, or even interested physicians can refer to the ClinicalTrials
.gov database to see whether trial data as reported reflect the planned study design.51 This
retrospective check could alleviate concerns about
the possibility that trial outcomes were changed
after the data were gathered and analyzed. However, the information provided to this database
may have missing values or may be of poor quality.51,52 We do not have empirical data that address whether concordance between the study
design and the reporting of results influences
physicians’ perceptions of methodologic rigor.
We found that physicians assigned the highest
level of credibility to NIH-funded trials. Thus, an
increase in the number of clinical trials funded
by the NIH or by the new Patient-Centered Outcomes Research Institute might reduce clinicians’
skepticism and lead to more data-driven changes
in practice.53 Despite the initial financial outlay,
such publicly funded trials are likely to save more
than they cost.54 Partnerships between the NIH
and industry55 may also serve this purpose if
their jointly funded trials feature characteristics
that are a routine part of NIH-funded trials, including data and safety monitoring boards and
public reporting of protocols.
It is reassuring that the physicians in our study
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were attentive to the level of methodologic rigor.
They also clearly took notice of funding sources
for trials, according greater credibility and import to NIH-funded research than to industryfunded research. Although attention to potential
sources of bias is necessary, such skepticism apparently can also reduce the credibility and acceptance of even high-quality research that is
industry-supported. Financial disclosure is important, but more fundamental strategies, such
as avoiding selective reporting of results in reports of industry-sponsored trials, ensuring protocol and data transparency, and providing an
independent review of end points, will be needed to more effectively promote the translation of
high-quality clinical trials — whatever their funding source — into practice.
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